After a clinical study discovered two low doses of Covid-19 to be safe and gave a “robust” immune response, Moderna on Wednesday announced its intention to seek urgent authorization for its Covid-19 vaccine in children under six, setting the stage for the first shots for children under 5 who are yet to get vaccinated against the covid.

Important Facts to Know

  • Around 4,200 children aged two to six, and around 2,500 toddlers aged six months to two years, took part in the study, which was not peer reviewed.
  • The two doses of 25 g (micrograms) each given to the children were “well tolerated” and the side effects were consistent with adults, majority of which were “mild to moderate” and more commonly reported after the second dosage.
  • Moderna’s CEO, Bancel, said the data would be used to get emergency permission from authorities worldwide “as soon as possible” to deploy Moderna’s vaccine for children between the ages of six months and six years.
  • Moderna has begun the FDA application process for emergency authorisation for children aged six to twelve years, using two 50g doses, as Balcel said on Wednesday. This medication has been previously authorized by authorities in Australia, Canada, and the European Union.

What to Watch For

Boosters! A decrease in effectiveness after two doses was seen in accordance with what is observed in adults when the omicron form predominated throughout the experiment. There were no occurrences of severe Covid-19 among the groups investigated, making it difficult to determine the vaccine’s effectiveness in preventing severe disease, hospitalization, and death. Booster injections for all pediatric groups from six months and up are being evaluated by Moderna, according to the company. An omicron-specific component will be added to the company’s original shot in order to evaluate both the original shot and its booster.


It will be the second option for youngsters between the ages of five and 12 if Moderna’s Covid injection is approved by the FDA. Kids under the age of five have been denied access to Pfizer and BioNTech’s vaccine after regulators expressed worries about its efficacy for that age range. The postponement will allow the business time to gather additional data on a third dosage in the regimen, which experts think will demonstrate stronger levels of immunization and should be accessible around April, aggravating parents who have small children who cannot obtain immunizations.


According to statistics compiled by the American Academy of Pediatrics as of the middle of March, immunization rates among kids who are eligible vary greatly throughout the country. The number of kids aged five to eleven who have gotten at least one dosage varies from 15 to 65 percent between states, but the national average is roughly one-third of that age group (around 27 percent have had both doses). Two-thirds of 12-17-year-olds have gotten at least one dosage, and 57% of them have received both. The argument for immunizing children differs from that for adults because of the lower risk of major side effects from the Covid-19 vaccine in children. Experts fear it may be difficult to convince parents to vaccinate their children if official data continues to indicate a downward trend in the number of instances. As in the United States, Europe has seen an increase in the number of cases, with certain nations seeing a record number.